ArticleThe Journal of antimicrobial chemotherapy2026
The tissue distribution and pharmacokinetics of [14C]-olorofim following intravenous dosing in the rat.
Article in The Journal of antimicrobial chemotherapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Antifungal exposure inAntimicrobial agents and chemotherapy · 2026Article
- In Vitro Evaluation of Olorofim and Amphotericin B Combination Therapy AgainstJournal of fungi (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo evaluate the penetration of olorofim, a novel antifungal agent into the tissues of the rat. MATERIALS AND
methodsQuantitative whole-body autoradiography was used to assess the distribution and tissue penetration in male and female rats following a single 2-hour IV infusion of [14C]-olorofim.
resultsRadioactivity was rapidly and extensively distributed throughout many tissues in both sexes with maximal concentrations observed soon after start of the infusion. Thereafter radioactivity declined and at 336 h (final timepoint), concentrations of radioactivity in most tissues were below the limit of quantification. The pattern of radioactive distribution was similar at all timepoints with concentrations greatest in liver, kidney cortex, adrenal cortex, abdominal and brown fat; the lowest concentrations were observed in the whole eye and at the bone surface (with levels similar to plasma in bone marrow and uveal tract/retina). Tissue:plasma radioactivity concentration ratios for most tissues were above unity during the period 2.25 to 72 h post-start of infusion. Radioactivity was detected in tissues frequently reported as sites of systemic fungal infections such as the lung, brain, kidney, bone and eye. Pharmacokinetic analyses showed that at early timepoints >75% of circulating radiolabelled material was intact olorofim confirming that olorofim is present in these key tissues at levels similar to or exceeding those seen in plasma.
conclusionsOlorofim distributes widely into rat tissues including those frequently infected by fungi, indicating its potential to treat systemic fungal infections caused by susceptible species, a finding in agreement with recent clinical reporting from a Phase 2 trial.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.